

Cover Story
Capitol Hill
The Centers for Medicare & Medicaid Services is planning a 33.4% cut to the reimbursement payments hospitals receive for all drugs acquired through the 340B program, according to a draft guidance published on July 7.
Cancer Policy


In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- Brawley: ACS prostate cancer screening guideline should say no to “mass screening”
- NCI’s Letai, FDA’s Diamantas identify strategies to speed up cancer trials
Letai: 150 days to start a cancer trial is too long—cancer centers need to accept a little risk - ACS strengthens recommendation for prostate cancer screening
Many will hear the endorsement and ignore the limitations - Kay “Taddy” Dickersin, NBCC co-founder, dies at 74
- CMS rule cuts overall oncology payments by estimated 2%
Final rule slashes 340B, moves toward site-neutrality - In the 90s, Barry Kramer persuaded NCI to get out of the business of screening guidelines
At the time, USPSTF was better equipped to do the job. Is it still?















